Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With …
https://www.pfizer.com/news/announcements/pfizer-and-biontech-advance-covid-19-vaccine-strategy-study-start-next
Jul 27, 2022 · NEW YORK and MAINZ, Germany, July 27, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level.
DA: 62 PA: 36 MOZ Rank: 16